These findings underpin the therapeutic properties of Ca2+-signaling modulation in AP and add the BH4 domains of Bcl-2 and Bcl-XL to the arsenal of tools with the therapeutic potential to reduce AP burden by limiting the excessive RyR activity and cell necrosis. The gene discussed is BCL2; the disease is alkaline phosphatase measurement.